Baxter Stock Plummets 15% After Mixed Q3 Earnings – What Investors Should Know
Mixed Third-Quarter Financial Results Baxter’s Q3 showed a mixed picture. Revenue from continuing operations rose about 5% year-over-year to $2.84 billion, helped by strong performance in its Pharmaceuticals and Healthcare Systems units baxter.com